Syndax Pharmaceuticals reported second quarter 2026 financial results ending June 30, 2026. Total revenue reached $72.8 million, a 92% year-over-year increase, driven by Revuforj net revenue of $54.7 million and Niktimvo collaboration revenue of $18.1 million. The company reported a net loss attributable to common stockholders of $49.4 million, or $0.55 per share, for the six months ended June 30, 2026. Syndax maintains a cash position of $575.1 million and expects full-year R&D plus SG&A expenses of approximately $400 million. The company announced new pipeline assets SNDX-4321 for NSCLC and SNDX-62122 for myelofibrosis, with topline data expected in the fourth quarter 2026 from Phase 2 trials of axatilimab in IPF and frontline cGVHD. Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies.
